97 related articles for article (PubMed ID: 17613445)
1. Physicians' efficacy requirements for prescribing medications to persons with Alzheimer's disease.
Oremus M; Wolfson C; Bergman H; Vandal AC
Can J Aging; 2007; 26(2):139-48. PubMed ID: 17613445
[TBL] [Abstract][Full Text] [Related]
2. How physicians approach advance care planning in patients with mild to moderate Alzheimer's disease.
Cavalieri TA; Latif W; Ciesielski J; Ciervo CA; Forman LJ
J Am Osteopath Assoc; 2002 Oct; 102(10):541-4. PubMed ID: 12401040
[TBL] [Abstract][Full Text] [Related]
3. Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors.
Robinson M; Rowett D; Leverton A; Mabbott V
Pharmacoepidemiol Drug Saf; 2009 Aug; 18(8):659-64. PubMed ID: 19548222
[TBL] [Abstract][Full Text] [Related]
4. Caregiver acceptance of adverse effects and use of cholinesterase inhibitors in Alzheimer's disease.
Oremus M; Wolfson C; Vandal AC; Bergman H; Xie Q
Can J Aging; 2007; 26(3):205-12. PubMed ID: 18238727
[TBL] [Abstract][Full Text] [Related]
5. Drug prescription in mild cognitive impairment: the physicians' perspective in Italy.
Frisoni GB; Canu E; Geroldi C; Zanetti O; Zacchi V
Int J Geriatr Psychiatry; 2006 Nov; 21(11):1071-7. PubMed ID: 16955446
[TBL] [Abstract][Full Text] [Related]
6. Treatment disparities in medication prescribing for Alzheimer's: disease among ethnic groups.
Perryman M; Lewis M; Rivers PA
J Health Care Finance; 2009; 35(4):64-73. PubMed ID: 20515010
[TBL] [Abstract][Full Text] [Related]
7. Practical treatment strategies for patients with Alzheimer's disease.
Christensen DD; Lin P
J Fam Pract; 2007 Dec; 56(12 Suppl New):S17-23. PubMed ID: 18664338
[TBL] [Abstract][Full Text] [Related]
8. [Treatment pattern of Alzheimer's disease with cholinesterase inhibitors (TRAIN study)].
Gil-Néciga E; Gobartt AL;
Rev Neurol; 2008 Apr 16-30; 46(8):461-4. PubMed ID: 18428102
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: a 21-month follow-up "real world" study.
Calabria M; Geroldi C; Lussignoli G; Sabbatini F; Zanetti O
Arch Gerontol Geriatr; 2009; 49(1):e6-11. PubMed ID: 18768226
[TBL] [Abstract][Full Text] [Related]
10. Family physicians' recommendations for the treatment of Alzheimer's disease.
Werner P
Am J Alzheimers Dis Other Demen; 2006 Dec-2007 Jan; 21(6):403-10. PubMed ID: 17267372
[TBL] [Abstract][Full Text] [Related]
11. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
Cortes F; Portet F; Touchon J; Vellas B
J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of Alzheimer's disease utilising the best available evidence-based medicine -- utopia?].
Stoppe G; Pirk O; Haupt M
Gesundheitswesen; 2005 Jan; 67(1):20-6. PubMed ID: 15672302
[TBL] [Abstract][Full Text] [Related]
13. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
14. Primary care physicians' attitudes related to cognition enhancers in early dementia: a representative eight-year follow-up study in Lower Saxony, Germany.
Maeck L; Haak S; Knoblauch A; Stoppe G
Int J Geriatr Psychiatry; 2008 Apr; 23(4):415-21. PubMed ID: 17907276
[TBL] [Abstract][Full Text] [Related]
15. Prescribing patterns for Alzheimer disease: survey of Canadian family physicians.
Hillmer M; Krahn M; Hillmer M; Pariser P; Naglie G
Can Fam Physician; 2006 Feb; 52(2):208-9. PubMed ID: 16926965
[TBL] [Abstract][Full Text] [Related]
16. Influences of attitudes on family physicians' willingness to prescribe long-acting opioid analgesics for patients with chronic nonmalignant pain.
Nwokeji ED; Rascati KL; Brown CM; Eisenberg A
Clin Ther; 2007; 29 Suppl():2589-602. PubMed ID: 18164924
[TBL] [Abstract][Full Text] [Related]
17. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?
Vellas B; Andrieu S; Cantet C; Dartigues JF; Gauthier S
J Nutr Health Aging; 2007; 11(4):338-41. PubMed ID: 17653494
[TBL] [Abstract][Full Text] [Related]
18. What Belgian geriatricians tell their patients with Alzheimer's disease and why: a national survey.
Segers K
Acta Neurol Belg; 2009 Dec; 109(4):283-93. PubMed ID: 20120208
[TBL] [Abstract][Full Text] [Related]
19. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
20. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
